Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Short Interest Down 17.9% in March

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) saw a large drop in short interest during the month of March. As of March 31st, there was short interest totalling 104,400 shares, a drop of 17.9% from the March 15th total of 127,100 shares. Based on an average trading volume of 129,800 shares, the short-interest ratio is currently 0.8 days. Currently, 0.6% of the shares of the company are sold short.

Analyst Ratings Changes

Several brokerages have recently issued reports on ENLV. HC Wainwright boosted their price objective on Enlivex Therapeutics from $6.00 to $7.00 and gave the company a “buy” rating in a report on Monday, March 24th. D. Boral Capital reissued a “buy” rating and issued a $13.00 price target on shares of Enlivex Therapeutics in a research note on Monday.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ENLV. Renaissance Technologies LLC raised its position in Enlivex Therapeutics by 112.6% in the fourth quarter. Renaissance Technologies LLC now owns 158,992 shares of the company’s stock valued at $186,000 after purchasing an additional 84,203 shares during the period. Two Sigma Securities LLC acquired a new position in Enlivex Therapeutics in the fourth quarter valued at about $26,000. Finally, Millennium Management LLC purchased a new position in Enlivex Therapeutics during the fourth quarter worth about $742,000. 1.02% of the stock is currently owned by institutional investors and hedge funds.

Enlivex Therapeutics Trading Up 1.7 %

ENLV traded up $0.02 on Tuesday, hitting $0.90. 20,897 shares of the company’s stock were exchanged, compared to its average volume of 119,196. The firm has a 50-day moving average price of $1.02 and a 200-day moving average price of $1.16. The stock has a market cap of $19.16 million, a price-to-earnings ratio of -0.91 and a beta of 0.85. Enlivex Therapeutics has a fifty-two week low of $0.81 and a fifty-two week high of $1.84.

Enlivex Therapeutics (NASDAQ:ENLV) last released its earnings results on Monday, March 31st. The company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.07). On average, equities analysts predict that Enlivex Therapeutics will post -0.7 EPS for the current year.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.